Multiple myeloma (MM) is a blood cancer in which the bone marrow produces an overabundance of malignant plasma cells that emerge into the bloodstream. Ultimately, the proliferation of plasma cells can cause bone damage, anemia, low white blood cell counts, and kidney failure. Approximately 25,000 cases of MM are diagnosed in the U.S. annually, with three quarters of affected individuals over 70 years of age. There is no cure for multiple myeloma, but its progression can be relatively slow in many individuals, often involving multiple rounds of remission after treatment followed by a subsequent relapse. Recent advances in therapy have greatly improved the disease’s prognosis.
Interventions of interest:
Carfilzomib (Kyprolis®, Onyx) with lenalidomide (Revlimid®, Celgene) and dexamethasone
Daratumumab (Darzalex®, Janssen Biotech) monotherapy
Elotuzumab (Empliciti®, Bristol Myers-Squibb) with lenalidomide and dexamethasone
Ixazomib (Ninlaro®, Takeda) with lenalidomide and dexamethasone
Panobinostat (Farydak®, Novartis Pharmaceuticals Corp.) with bortezomib (Velcade®, Takeda Millennium) and dexamethasone
Pomalidomide (Pomalyst®, Celgene) with low-dose dexamethasone
Date of review: May 2016
1335 South Lindbergh Boulevard
St. Louis, MO
At its inaugural meeting, the Midwest CEPAC convened to discuss the comparative clinical effectiveness and value of therapies for multiple myeloma.
Public comments received on ICER’s Draft Evidence Report
A summary of comments received on ICER’s report on treatments for multiple myeloma, and ICER’s response to comments.